Achieve Life Sciences
Equity Research
Rating:
OUTPERFORM
Market Cap:
$128.2
Price Target:
$14.00
Cash:
$61.3M
Debt:
$17.65M
Enterprise Value:
$113M
Latest Research Note:
Previous Research Notes:
08.05.25: ACHV: NDA Submission Imminent with $45M Cash Infusion Supporting Next Phase
10.02.24: ACHV: 2Q24 Results Highlight Progress on Nicotine Dependence Strategy
5.10.24: ACHV: 1Q Review: ORCA-OL on Track; Reiterating $14 PT and OUTPERFORM Rating
5.6.24: ACHV: 1Q Preview: ORCA-OL Nearing Launch; Reiterating $14 Price Target and OUTPERFORM
03.05.24 ACHV: Offering Provides Cash and Clarity to Commercialization Reducing PT to $14
11.15.23 ACHV: 3Q Review: Lining Up the Ducks; Reiterate OUTPERFORM Rating & $20 PT
11.07.23: ACHV: 3Q Preview: Calm Before the Catalysts; Reiterate OUTPERFORM Rating & $20 PT
8.17.23: 2Q Review: NDA Moving Forward…Partner or Buy?; Reiterate OUTPERFORM Rating & $20 PT